Azithromycin versus placebo for the treatment of HIV-associated chronic lung disease in children and adolescents (BREATHE trial): study protocol for a randomised controlled trial

Table 2 Secondary outcomes

Outcome	Time point
Time to first respiratory exacerbation
Time to death
Number of acute exacerbations	By 12 months
Number of hospitalisations	By 12 months
Number of mild, moderate and severe adverse events	By 12 months
Mean weight-for-age z-score adjusted for baseline	By 12 months
Incidence of infectious episodes (Salmonella typhi, malaria, gastroenteritis)	By 12 months
Durability of effect (FEV₁ z-score)	18 months

ISSN: 1745-6215